pixantrone has been researched along with Lymphoma, Large B-Cell, Diffuse in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Deuster, O; Dreyling, MH; Ernst, T; Frontzek, F; Hess, G; Hüttmann, A; Keller, U; Lenz, G; Marks, R; Pott, C; Rosenwald, A; Ruckes, C; Theobald, M; Trautmann, M; Viardot, A; Witzens-Harig, M | 1 |
| Cencini, E; Fabbri, A | 1 |
| Bocchia, M; Cencini, E; Consoli, C; Cuccaro, A; De Marco, F; Fabbri, A; Ghio, F; Rocco, M; Simonetti, F | 1 |
| Bregni, M; Bugli, A; Mitterer, M; Musuraca, G; Piazza, F; Pinto, A; Spione, M; Zinzani, PL | 1 |
| Menna, P; Minotti, G; Salvatorelli, E | 1 |
| Argnani, L; Casadei, B; Malaspina, F; Pellegrini, C; Zinzani, PL | 1 |
| Bertoni, F; Cattan, V; Egorov, A; Han, H; Minotti, G | 1 |
| Długosz-Danecka, M; Jurczak, W; Rivas Navarro, F | 1 |
| Busschbach, JJV; Ismail, SY; Lugtenburg, PJ; Siemes, C; van Hoogdalem, LE | 1 |
| Cernohous, P; Engert, A; Herbrecht, R; Le Gouill, S; Macdonald, D; Machida, C; Myint, H; Saleh, A; Singer, J; van der Jagt, R; Wilhelm, M | 1 |
| Aung, T; Becker, S; Chapuy, B; Jacob, R; Koch, R; Sinzig, U; Truemper, L; Venkataramani, V; Vogel, D; von Mach, T; Wenzel, D; Wulf, GG | 1 |
| Ardeshna, K; Bailey, C; Chaidos, A; Collins, GP; Cwynarski, K; Eden, D; Eyre, DW; Eyre, TA; Hatton, CS; Jasani, P; Kothari, J; Linton, KM; Osborne, WL; Rohman, P; Rowntree, C; Shankara, P | 1 |
| Allievi, C; Bernareggi, A; Cabanillas, F; Fayad, L; Laffranchi, B; Levine, AM; Lim, ST; Modiano, M; Tulpule, A | 1 |
2 review(s) available for pixantrone and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Pixantrone: novel mode of action and clinical readouts.
Topics: Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Mitoxantrone; Survival Rate | 2018 |
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2019 |
3 trial(s) available for pixantrone and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2022 |
Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Failure; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Stroke Volume; Survival; Survival Rate; Topoisomerase II Inhibitors; Treatment Outcome; Troponin T; Vincristine | 2013 |
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Salvage Therapy; Treatment Outcome | 2007 |
8 other study(ies) available for pixantrone and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional TUSCAN Lymphoma Network)-Authors' reply to Morris and colleagues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab | 2022 |
Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies | 2023 |
Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Female; Genetic Diseases, X-Linked; Humans; Isoquinolines; Italy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Registries; Retrospective Studies; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome | 2021 |
The Reality of Pixantrone in Real Life.
Topics: Humans; Isoquinolines; Italy; Lymphoma, Large B-Cell, Diffuse; Registries | 2021 |
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma.
Topics: Adult; Antineoplastic Agents; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2017 |
Patients' decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study.
Topics: Decision Making; Humans; Informed Consent; Isoquinolines; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Netherlands; Patient Preference; Quality of Life; Research Design; Treatment Outcome | 2019 |
Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone.
Topics: Anthracyclines; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Nucleus; Cytostatic Agents; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exosomes; Humans; Indomethacin; Isoquinolines; Lymphoma, Large B-Cell, Diffuse | 2016 |
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Female; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2016 |